HOME >> BIOLOGY >> NEWS
New Tuberculosis Vaccine Candidate Developed: Improved Delivery Of Antigens By Current Vaccine BCG (Bacille Calmette-Gurin)

Scientists at the Max Planck Institute for Infection Biology, Berlin and at the University Clinics of Ulm have developed a putative vaccine candidate against Mycobacterium tuberculosis, the causative agent of tuberculosis. Their data have been published in the Proceedings of the National Academy of Sciences U.S.A. on April 28, 1998.

Although tuberculosis belongs to the "old" diseases, it still remains a significant global health problem. Tuberculosis is responsible for 3 million deaths annually - more than at any time-point before and more than any other infectious agent. Moreover, it has been estimated that half a billion people will suffer from tuberculosis by the year 2050. Already in 1927, a vaccine was developed which was termed bacille Calmette-Gurin (BCG) to honour the scientists who attenuated Mycobacterium bovis by more than 230 passages on bile glycerol agar. In many countries the only measure for tuberculosis control has been vaccination with BCG. General agreement exists that BCG can protect or at least ameliorate severe forms of tuberculosis in children. Yet, it seems to be of low or no protective value in adults.

M. tuberculosis belongs to the group of intracellular bacteria that replicate within the phagosomal vacuoles of resting macrophages and protection against tuberculosis depends on T cell-mediated immunity. Major histocompatiblity complex (MHC) class II-restricted CD4 T helper cells and MHC class I-restricted cytotoxic CD8 T cells are stimulated during M.tuberculosis infection, but the current BCG vaccine fails to prime CD8 T cells for tuberculosis prevention.

Over the last few years, Juergen Hess and Stefan H.E. Kaufmann from the Max Planck Institute for Infection Biology in Berlin and the University Clinics of Ulm developed recombinant ( r )- BCG strains which secrete pore-f
'"/>

Contact: Juergen Hess
hess@mpiib-berlin.mpg.de
+49-30-2802-6483
Max-Planck-Gesellschaft
28-Apr-1998


Page: 1 2

Related biology news :

1. Scientists Identify Molecular Target For Tuberculosis Drug Treatment
2. Scientists Unlock Mystery Behind Proteins That Keep Tuberculosis Bacteria Alive; Finding Leads To Research Into New Drug Treatments
3. Hope Clinic of Emory Vaccine Center receives CDC contract
4. Vaccines against foodborne disease on horizon
5. GenVec, U.S. NMRC, and PATHs Malaria Vaccine Initiative partner to expand malaria vaccine efforts
6. Vaccine technique shows potential against common form of lung cancer
7. Fighting fire with fire? Vaccine based on chimp virus shows promise against HIV
8. Emory Vaccine Research Center study identifies specific gene required for long-term immunity
9. Vaccine prevents stroke in rats
10. Vaccine puts blood-sucking ticks off their food
11. Vaccine protects against fatal West Nile complication

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... ... In an upcoming episode scheduled for the fall of 2020, Advancements with ... Check local listings for more info. , Today, the majority of testing is performed ... throughout the country. Results are then available several days later. Now, in an effort ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... antibody development services, today announced that the company has received ISO9001:2015 certification ... pharmaceutical, diagnostics, and research industries. The decision to pursue ISO9001 accreditation demonstrates ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation ... binding assays (LBA) have dominated this area. However, the use of mass spectrometry in ... This now necessitates the question “How do you choose which approach to use (LBA ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions ... as MediVet Biologics since its formation in 2016, the company is relaunching itself under ... build on its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... Mass. and SOMERSET, N.J (PRWEB) , ... July ... ... leading genome editing company, and Catalent, the leading global provider of advanced delivery ... consumer health products, today announced that they have entered into a strategic partnership ...
(Date:7/18/2020)... ... ... After research model surgery and catheter implantation, the long journey of catheter ... of a successful study, while protecting and accessing the catheter or device post-surgery is ... from Envigo in a live webinar on Wednesday, August 5, ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... of Technology (MIT) has expanded the company’s exclusive license to include clinical ... the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ ...
Breaking Biology Technology:
Cached News: